Cargando…
Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening
Familial amyloid polyneuropathy is a hereditary systemic amyloidosis caused by a mutation in the transthyretin (TTR) gene. Amyloid deposits in tissues of patients contain not only full-length TTR but also C-terminal TTR fragments. However, in vivo models to evaluate the pathogenicity of TTR fragment...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294829/ https://www.ncbi.nlm.nih.gov/pubmed/30552363 http://dx.doi.org/10.1038/s41598-018-36357-5 |
_version_ | 1783380795941978112 |
---|---|
author | Tsuda, Yukimoto Yamanaka, Kunitoshi Toyoshima, Risa Ueda, Mitsuharu Masuda, Teruaki Misumi, Yohei Ogura, Teru Ando, Yukio |
author_facet | Tsuda, Yukimoto Yamanaka, Kunitoshi Toyoshima, Risa Ueda, Mitsuharu Masuda, Teruaki Misumi, Yohei Ogura, Teru Ando, Yukio |
author_sort | Tsuda, Yukimoto |
collection | PubMed |
description | Familial amyloid polyneuropathy is a hereditary systemic amyloidosis caused by a mutation in the transthyretin (TTR) gene. Amyloid deposits in tissues of patients contain not only full-length TTR but also C-terminal TTR fragments. However, in vivo models to evaluate the pathogenicity of TTR fragments have not yet been developed. Here, we generated transgenic Caenorhabditis elegans strains expressing several types of TTR fragments or full-length TTR fused to enhanced green fluorescent protein in the body wall muscle cells and analyzed the phenotypes of the worms. The transgenic strain expressing residues 81–127 of TTR, which included the β-strands F and H, formed aggregates and caused defective worm motility and a significantly shortened lifespan compared with other strains. These findings suggest that the C-terminal fragments of TTR may contribute to cytotoxicity of TTR amyloidosis in vivo. By using this C. elegans model system, we found that (−)-epigallocatechin-3-gallate, a major polyphenol in green tea, significantly inhibited the formation of aggregates, the defective motility, and the shortened lifespan caused by residues 81–127 of TTR. These results suggest that our newly developed C. elegans model system will be useful for in vivo pathological analyses of TTR amyloidosis as well as drug screening. |
format | Online Article Text |
id | pubmed-6294829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-62948292018-12-24 Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening Tsuda, Yukimoto Yamanaka, Kunitoshi Toyoshima, Risa Ueda, Mitsuharu Masuda, Teruaki Misumi, Yohei Ogura, Teru Ando, Yukio Sci Rep Article Familial amyloid polyneuropathy is a hereditary systemic amyloidosis caused by a mutation in the transthyretin (TTR) gene. Amyloid deposits in tissues of patients contain not only full-length TTR but also C-terminal TTR fragments. However, in vivo models to evaluate the pathogenicity of TTR fragments have not yet been developed. Here, we generated transgenic Caenorhabditis elegans strains expressing several types of TTR fragments or full-length TTR fused to enhanced green fluorescent protein in the body wall muscle cells and analyzed the phenotypes of the worms. The transgenic strain expressing residues 81–127 of TTR, which included the β-strands F and H, formed aggregates and caused defective worm motility and a significantly shortened lifespan compared with other strains. These findings suggest that the C-terminal fragments of TTR may contribute to cytotoxicity of TTR amyloidosis in vivo. By using this C. elegans model system, we found that (−)-epigallocatechin-3-gallate, a major polyphenol in green tea, significantly inhibited the formation of aggregates, the defective motility, and the shortened lifespan caused by residues 81–127 of TTR. These results suggest that our newly developed C. elegans model system will be useful for in vivo pathological analyses of TTR amyloidosis as well as drug screening. Nature Publishing Group UK 2018-12-14 /pmc/articles/PMC6294829/ /pubmed/30552363 http://dx.doi.org/10.1038/s41598-018-36357-5 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Tsuda, Yukimoto Yamanaka, Kunitoshi Toyoshima, Risa Ueda, Mitsuharu Masuda, Teruaki Misumi, Yohei Ogura, Teru Ando, Yukio Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening |
title | Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening |
title_full | Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening |
title_fullStr | Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening |
title_full_unstemmed | Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening |
title_short | Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening |
title_sort | development of transgenic caenorhabditis elegans expressing human transthyretin as a model for drug screening |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294829/ https://www.ncbi.nlm.nih.gov/pubmed/30552363 http://dx.doi.org/10.1038/s41598-018-36357-5 |
work_keys_str_mv | AT tsudayukimoto developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening AT yamanakakunitoshi developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening AT toyoshimarisa developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening AT uedamitsuharu developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening AT masudateruaki developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening AT misumiyohei developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening AT ogurateru developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening AT andoyukio developmentoftransgeniccaenorhabditiselegansexpressinghumantransthyretinasamodelfordrugscreening |